Mentari Therapeutics, Inc. (NASDAQ:MTRI)
| Market Cap | $10.49M+5.5% |
| Revenue (ttm) | $2.06B+38958.8% |
| Net Income | -$12.41M-40.1% |
| EPS | -$31.11+58.0% |
| Shares Out | 549.37K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,332.311 |
| Open | $19.02 |
| Previous Close | $18.35 |
| Day's Range | $18.00 - $20.00 |
| 52-Week Range | $5.75 - $23.30 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Feb 10, 2027 |
About MTRI
Mentari Therapeutics, Inc. is a biotechnology company, which engages in developing therapies for migraine prevention. Its portfolio includes MT-001 and MT-002. The company was founded on June 13, 2025 and is headquartered in Waltham, MA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Feb 10, 2027Earnings report
$MTRI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MTRI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MTRI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MTRI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MTRI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MTRI from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from MTRI’s recent data — informational, not investment advice